Temgesic 0.3 mg/ml inj. sol. i.v./i.m. amp. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

temgesic 0.3 mg/ml inj. sol. i.v./i.m. amp.

eumedica pharmaceuticals gmbh - buprenorphine hydrochloride 0,32 mg/ml - eq. buprenorphine 0,3 mg/ml - solution for injection - 0,3 mg/ml - buprenorphine hydrochloride 0.32 mg/ml - buprenorphine

Buprecare 0,3 mg/ml inj. sol. i.m. amp. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

buprecare 0,3 mg/ml inj. sol. i.m. amp.

ecuphar sa-nv - buprenorphine hydrochloride 0,32 mg/ml - eq. buprenorphine 0,3 mg/ml - solution for injection - 0,3 mg/ml - buprenorphine hydrochloride 0.32 mg/ml - buprenorphine - dog; cat

Bupredine Multidose 0,3 mg/ml inj. sol. i.v./i.m. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bupredine multidose 0,3 mg/ml inj. sol. i.v./i.m. vial

le vet. (beheer) b.v. - buprenorphine hydrochloride 0,324 mg/ml - eq. buprenorphine 0,3 mg/ml - solution for injection - 0,3 mg/ml - buprenorphine hydrochloride 0.324 mg/ml - buprenorphine - horse; dog; cat

Buprenodale Multidose 0,3 mg/ml inj. sol. i.m./i.v. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

buprenodale multidose 0,3 mg/ml inj. sol. i.m./i.v. vial

dechra regulatory b.v. - buprenorphine hydrochloride 0,324 mg/ml - eq. buprenorphine 0,3 mg/ml - solution for injection - 0,3 mg/ml - buprenorphine hydrochloride 0.32 mg/ml - buprenorphine - dog; horse; cat

Vetergesic Multidosis 0,3 mg/ml inj. sol. i.m./i.v. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

vetergesic multidosis 0,3 mg/ml inj. sol. i.m./i.v. vial

ceva santé animale sa-nv - buprenorphine hydrochloride 0,32 mg/ml - eq. buprenorphine 0,3 mg/ml - solution for injection - 0,3 mg/ml - buprenorphine hydrochloride 0.32 mg/ml - buprenorphine - dog; cat

Temgesic New Zealand - English - Medsafe (Medicines Safety Authority)

temgesic

pharmacy retailing (nz) ltd t/a healthcare logistics - buprenorphine hydrochloride 0.324 mg/ml equivalent to 0.3 mg/ml buprenorphine; buprenorphine hydrochloride 0.324 mg/ml equivalent to buprenorphine 0.3 mg/ml - solution for injection - 0.3 mg/ml - active: buprenorphine hydrochloride 0.324 mg/ml equivalent to 0.3 mg/ml buprenorphine excipient: glucose hydrochloric acid water for injection active: buprenorphine hydrochloride 0.324 mg/ml equivalent to buprenorphine 0.3 mg/ml excipient: glucose monohydrate hydrochloric acid water for injection - temgesic injection is indicated for the short-term (not more than one week) management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain. temgesic is not recommended for use in children. temgesic does not have an approved role in opioid dependence rehabilitation programmes.

Buprecare 0.3 mg/ml Solution for Injection for Dogs and Cats Ireland - English - HPRA (Health Products Regulatory Authority)

buprecare 0.3 mg/ml solution for injection for dogs and cats

ecuphar nv - buprenorphine hydrochloride - solution for injection - 0.3 milligram(s)/millilitre - buprenorphine

BUPRENORPHINE HYDROCHLORIDE SUBLINGUAL tablet United States - English - NLM (National Library of Medicine)

buprenorphine hydrochloride sublingual tablet

contract pharmacy services-pa - buprenorphine hydrochloride (unii: 56w8mw3en1) (buprenorphine - unii:40d3scr4gz) - buprenorphine 2 mg - buprenorphine hydrochloride sublingual tablets are indicated for the treatment of opioid dependence and are preferred for induction. buprenorphine hydrochloride sublingual tablets should be used as part of a complete treatment plan to include counseling and psychosocial support. under the drug addiction treatment act (data) codified at 21 u.s.c. 823(g), prescription use of this product in the treatment of opioid dependence is limited to healthcare providers who meet certain qualifying requirements, and who have notified the secretary of health and human services (hhs) of their intent to prescribe this product for the treatment of opioid dependence and have been assigned a unique identification number that must be included on every prescription. buprenorphine hydrochloride sublingual tablets should not be administered to patients who have been shown to be hypersensitive to buprenorphine, as serious adverse reactions, including anaphylactic shock, have been reported [see warnings and precautions (

BUPRENORPHINE HYDROCHLORIDE- buprenorphine hydrochloride tablet United States - English - NLM (National Library of Medicine)

buprenorphine hydrochloride- buprenorphine hydrochloride tablet

lake erie medical dba quality care products llc - buprenorphine hydrochloride (unii: 56w8mw3en1) (buprenorphine - unii:40d3scr4gz) - buprenorphine 8 mg - buprenorphine sublingual tablets is indicated for the treatment of opioid dependence and is preferred for induction. buprenorphine sublingual tablets should be used as part of a complete treatment plan to include counseling and psychosocial support. under the drug addiction treatment act (data) codified at 21 u.s.c. 823(g), prescription use of this product in the treatment of opioid dependence is limited to physicians who meet certain qualifying requirements, and who have notified the secretary of health and human services (hhs) of their intent to prescribe this product for the treatment of opioid dependence and have been assigned a unique identification number that must be included on every prescription. buprenorphine sublingual tablets should not be administered to patients who have been shown to be hypersensitive to buprenorphine, as serious adverse reactions, including anaphylactic shock, have been reported. [see warnings and precautions (5.8)]. pregnancy category c risk summary there are no adequate

BUPRENORPHINE HYDROCHLORIDE injection United States - English - NLM (National Library of Medicine)

buprenorphine hydrochloride injection

par pharmaceutical, inc. - buprenorphine hydrochloride (unii: 56w8mw3en1) (buprenorphine - unii:40d3scr4gz) - buprenorphine 0.324 mg in 1 ml - buprenorphine hydrochloride injection is indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings: addiction, abuse, and misuse] reserve buprenorphine for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: - have not been tolerated, or are not expected to be tolerated, have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia. buprenorphine hydrochloride is contraindicated in patients with: - significant respiratory depression [see warnings]. significant respiratory depression [see warnings]. - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings]. acute or severe bronchial asthma i